Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.55 |
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358409 | 0.88 | CNR1 (0.56) | CNR1CNR2ACHE | |
| SCHEMBL739526 | 0.87 | CNR1 (0.64) | CNR1CNR2ACHEKDM4ENPC1 | |
| SCHEMBL4277527 | 0.85 | CNR1 (0.55) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL6358574 | 0.84 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL6357850 | 0.83 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL6364012 | 0.83 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL6332827 | 0.82 | CNR1 (0.53) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL6359510 | 0.81 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL6358910 | 0.81 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL5350855 | 0.81 | CNR1 (0.56) | CNR1CNR2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005009974-A1 | IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026983-A1 | An imidazole compound containing an amine group is used in the treatment of diseases linked to the activation of the cannabinoid receptors in animals; eating disorders, weight loss, obesity, depression, bipolar disorders, psychoses, schizophrenia, substance abuse, alcoholism, Parkinson's disease, ADHD | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026983-A1 | An imidazole compound containing an amine group is used in the treatment of diseases linked to the activation of the cannabinoid receptors in animals; eating disorders, weight loss, obesity, depression, bipolar disorders, psychoses, schizophrenia, substance abuse, alcoholism, Parkinson's disease, ADHD | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885ACHE 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.